Home > Healthcare > Pharmaceuticals > Pharma Manufacturing > Peptide and Oligonucleotide CDMO Market
Peptide and Oligonucleotide CDMO Market Size
- Report ID: GMI8502
- Published Date: Mar 2024
- Report Format: PDF
Peptide and Oligonucleotide CDMO Market Size
Peptide and Oligonucleotide CDMO Market was valued at USD 2.3 billion in 2023 and is expected to register at a CAGR of over 12.1% from 2024 to 2032, due to the increasing demand for personalized medicine and targeted therapies, which require customized peptides and oligonucleotides. Additionally, the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and genetic disorders has led to a growing need for innovative therapeutic solutions, further fuelling the demand for peptide and oligonucleotide CDMO services.
Furthermore, advancements in biotechnology and the pharmaceutical industry have led to the development of more complex and potent peptides and oligonucleotides, creating opportunities for CDMOs to provide specialized manufacturing expertise. The expanding applications of peptides and oligonucleotides in areas such as diagnostics, drug delivery, and therapeutics are further driving the growth of the market.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Peptide and Oligonucleotide CDMO Market Size in 2023: | USD 2.3 Billion |
| Forecast Period: | 2024 - 2032 |
| Forecast Period 2024 - 2032 CAGR: | 12.1% |
| 2032 Value Projection: | USD 6.3 Billion |
| Historical Data for: | 2018 - 2023 |
| No. of Pages: | 135 |
| Tables, Charts & Figures: | 237 |
| Segments covered: | Product, Service Type, Application, End-use, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Frequently Asked Questions (FAQ) :
Peptide and Oligonucleotide CDMO Market Scope
